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Abstract: Bladder cancer is among the top ten most common cancers, with about ~380,000 new cases
and ~150,000 deaths per year worldwide. Tumor relapse following chemotherapy treatment has long
been a significant challenge towards completely curing cancer. We have utilized a patient-derived
bladder cancer xenograft (PDX) platform to characterize molecular mechanisms that contribute
to relapse following drug treatment in advanced bladder cancer. Transcriptomic profiling of
bladder cancer xenograft tumors by RNA-sequencing analysis, before and after relapse, following a
21-day cisplatin/gemcitabine drug treatment regimen identified methionine adenosyltransferase 1a
(MAT1A) as one of the significantly upregulated genes following drug treatment. Survey of patient
tumor sections confirmed elevated levels of MAT1A in individuals who received chemotherapy.
Overexpression of MAT1A in 5637 bladder cancer cells increased tolerance to gemcitabine and stalled
cell proliferation rates, suggesting MAT1A upregulation as a potential mechanism by which bladder
cancer cells persist in a quiescent state to evade chemotherapy.
Keywords: bladder cancer; drug resistance; methyltransferase; gemcitabine
1. Introduction
Bladder cancer is the eighth most common type of cancer in the United States, with an estimated
80,000 new cases reported each year [1]. The stage of disease at the time of diagnosis is critical for
determining patient outcome; the survival rate for cancers found at early stages is greater than 85%.
However, once the cancer has reached stages three or four and has progressed from the bladder to the
abdominal cavity or lymph nodes, the five-year survival rate drops below 50% [2]. Cancer becomes
increasingly challenging to treat as it metastasizes to other tissues. Routine standard of care with
first line chemotherapeutics typically result in tumor shrinkage, however, most cases relapse despite
initial chemotherapeutic sensitivity and the recurring tumor is usually drug resistant [3]. For almost
all cancer types, the emergence of drug resistance has long been a challenge in achieving a complete
cure. This phenomenon is widespread in that almost all cancers can become drug resistant and cancer
cells can become resistant to almost all types of therapeutic agents. Chemotherapy resistant cancer
cells then progress into more aggressive tumors, capable of both metastasizing to distant sites and
withstanding future drug treatments, ultimately contributing to a patient mortality [4].
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Advanced bladder cancer is commonly treated with nonspecific chemotherapeutics, such as
cisplatin and gemcitabine [3]. Cisplatin belongs to the platinum-based family of chemotherapeutics
while gemcitabine is a type of DNA synthesis inhibitor. While having slightly different mechanisms
of action, both rely on the rapidly dividing nature of cancer cells. Gemcitabine is an analog of
deoxycytidine that once inside a cell it becomes activated via phosphorylation, to be used as a
nucleoside during DNA synthesis. Inhibition of DNA synthesis is the most likely mechanism by
which gemcitabine causes cell death. Gemcitabine nucleotide incorporation into the elongating DNA
strand stalls the DNA polymerase. This action locks the drug onto the DNA rendering proofreading
enzymes incapable of removing gemicitabine-DNA adducts. Previous research has shown that high
levels of gemcitabine-DNA adducts in bladder cancer patients correlate with drug response [5].
While gemcitabine is a well-known chemotherapeutic agent, the molecular mechanisms by which
cells are rendered chemoresistant post remission have yet to be fully elucidated. Additionally,
dormancy-type mechanisms by which cells evade drug treatment can be applicable to other first line
nonspecific therapies that do not depend on cancer cell proliferation to render an effect.
Methionine adenosyltransferase 1a (MAT1A) is an enzyme that helps regulate an important
biological molecule, S-adenosylmethionine (SAM) that plays a key role in the methylation cycle [6].
The importance of S-adenosylmethionine has been a topic of increased interest as it relates to metabolism
and dysregulation of cancer cells [7,8], however, direct links between this protein and enhanced survival
during chemotherapy treatment have yet to be established. Here, we found that upregulation of MAT1A
correlates with increased resistance to gemcitabine treatment. Methyltransferases of various types have
been previously implicated in cancer progression, however for the first time, we showed that MAT1A
elevated levels confer a significant survival advantage in bladder cancer cells during drug exposure.
Here, we utilized RNA sequencing (RNA-seq) to identify transcripts differentially expressed in drug
relapsed patient-derived bladder cancer xenograft (PDX) tumors of bladder cancer when compared to
untreated tumors. We determined that transient upregulation of MAT1A in response to drug exposure
allowed cells to adopt a less proliferative state. This work has provided novel insights into the temporal
nature of gene regulation in response to nonspecific chemotherapy exposure. Furthermore, MAT1A
may have clinical applications as a biomarker of a drug resistant cell subpopulation.
2. Results
2.1. Significant Changes in the Transcriptome of Bladder Cancer Patient-Derived Xenografts are Associated
with Drug Relapse Following Treatment.
To identify molecular changes associated with chemotherapeutic resistance, RNA-seq was
performed on PDX tumors derived from human bladder cancer cells. Tumors were initiated by
delivering 3 × 106 tumor cells subcutaneously into NOD scid gamma (NSG) mice from two patient
tumor lines, BL0293 and BL0440, previously shown to be sensitive to cisplatin (CIS) and gemcitabine
(GEM) combination therapy [9]. A clinically relevant regimen of CIS/GEM was administered when
tumor size reached 100–150 mm3 and RNA was harvested and analyzed when relapsed tumors reached
~700 mm3 in size or when other Institutional Animal Care and Use Committee (IACUC) criteria were
met (Figure 1A). Both tumors initially responded to treatment as evidenced by a decrease in tumor size
and a reduction in growth rate during CIS/GEM administration; however, both lines relapsed and grew
at an accelerated rate after 35 days (Figure 1B,C), similar to other human-bladder cancer PDX lines
tested for sensitivity to chemotherapy [9]. The BL0293 tumors however, grew at much faster rate than
the BL0440 tumors, after the remission period (Figure 1B,C). The transcriptome from these relapsed
tumors was profiled and compared to phosphate buffered saline (PBS) treated tumors to identify
differentially expressed genes in relapsed tumors. In total, there were 96 genes that were significantly
upregulated (FDR p < 0.05) in BL0293 following chemotherapy and 255 genes that were significantly
downregulated. To a similar extent, we identified 289 transcripts significantly upregulated and 113
genes significantly downregulated in BL0440 relapsed tumors (Figure 2A).
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phosphate buffered saline (PBS) control mice (n = 3) treated concurrently with gemcitabine 
(intraperitoneally) and cisplatin (intravenously). Tumor growth was measured weekly for (B) BL0293 
and (C) BL0440. RNA was isolated from PBS and Rx tumors at last time point recorded. 
Figure 1. Patient-derived bladder cancer xenograft (PDX) tumors BL0293 and BL0440 relapse following
combination drug therapy. (A) Drug dosing was initiated when tumors reached ~100–150 mm3 in
size and occurred over 21 days with experimental mice (drug treated (Rx)) (n = 5) and phosphate
buffered saline (PBS) control mice (n = 3) treated concurrently with gemcitabine (intraperitoneally)
and cisplatin (intravenously). Tumor growth was measured weekly for (B) BL0293 and (C) BL0440.
RNA was isolated from PBS and Rx tumors at last time point recorded.
We found 37 genes to be significantly changed in response to drug treatment, in both models of
bladder cancer drug relapse (Figure 2B–D). Among the upregulated genes, there were 20 genes that
were upregulated when both PDX BL0293 and BL0440 relapsed following drug treatment, with 76
genes being upregulated only in BL0293 and 269 genes uniquely upregulated in BL0440 (Figure 2B).
Additionally, there were 17 genes downregulated in both PDX models, with 238 genes downregulated
in response to drug treatment in tumor BL0293 and 96 genes uniquely downregulated when tumor
BL0440 relapsed (Figure 2D). Common genes found to be most differentially expressed following
chemotherapeutic administration are listed in Table 1 and Table S1. MAT1A was one of the top
significantly upregulated genes with a fold change (FC) value of 6.66 and 3.40 once BL0293 and BL0440
tumors relapsed following treatment, respectively (Figure 2E).
Seven enriched pathways were determined from the 20 genes upregulated in both BL0293 and
BL0440 relapsed tumors (Table 2). Top pathway ontologies enriched included ‘Interferon alpha-beta
signaling’, ‘Metabolism’, ‘Transcriptional regulation’, and ‘Methylation’. MAT1A was included in
several top ontologies including ‘Metabolism of ingested SeMet, Sec, MeSec into H2Se’, ‘Methylation’,
‘Metabolism of amino acids and derivatives’, ‘Phase II conjugation’, and ‘Selenoamino acid metabolism’.
Top pathway ontologies based on shared downregulated genes include ‘Inflammasomes’ and
‘PKA-mediated phosphorylation of key metabolic factors’.
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Table 1. Top 20 upregulated genes in drug relapsed PDX tumors.
Ranking Gene Symbol Gene Name BL0293_FC BL0440_FC
1 MAGEA11 Melanoma-Associated Antigen 11 2.75 8.50
2 MAT1A Methionine Adenosyltransferase 1A 6.66 3.40
3 DIO2 Iodothyronine Deiodinase 2 3.04 6.72
4 PWWP2B PWWP Domain-Containing Protein 2B 4.91 3.67
5 PAGE2 Prostate-Associated Gene 2 Protein 4.68 2.67
6 FAM133A Family With Sequence Similarity 133 Member A 4.25 2.81
7 ABHD17C Abhydrolase Domain Containing 17C 2.37 4.53
8 LINC00839 Long Intergenic Non-Protein Coding RNA 839 2.75 3.62
9 OAS1 2′-5′-Oligoadenylate Synthetase 1 1.63 4.56
10 RSAD2 Radical S-Adenosyl Methionine Domain Containing 2 2.49 3.28
11 CMPK2 Cytidine/Uridine Monophosphate Kinase 2 1.80 3.67
12 HMGN5 High Mobility Group Nucleosome Binding Domain 5 2.80 2.49
13 ZNF300P1 Zinc Finger Protein 300 Pseudogene 1 2.64 1.91
14 SEPT14 Septin 14 1.75 2.57
15 CEBPA CCAAT Enhancer Binding Protein Alpha 2.09 1.81
16 KCNC4 Potassium Voltage-Gated Channel Subfamily C Member 4 1.66 2.19
17 NNMT Nicotinamide N-Methyltransferase 1.52 2.23
18 MPC1 Mitochondrial Pyruvate Carrier 1 1.69 1.71
19 ZNF385B Zinc Finger Protein 385B 1.70 1.52
20 CEBPD CCAAT Enhancer Binding Protein Delta 1.57 1.60
Table 2. Pathway ontologies of upregulated genes in relapsed, drug treated BL0293 and BL0440 PDX
tumors using ToppGene ToppFun suite.
Reactome Identifier Name p-Value
R-HSA-909733 Interferon alpha/beta signaling 1.324 × 10-5
R-HSA-2408508 Metabolism of ingested SeMet, Sec, MeSec into H2Se 2.084 × 10-5
R-HSA-381340 Transcriptional regulation of white adipocyte differentiation 2.142 × 10-5
R-HSA-156581 Methylation 6.927 × 10-5
R-HSA-71291 Metabolism of amino acids and derivatives 2.613 × 10-3
R-HSA-156580 Phase II conjugation 3.383 × 10-3
R-HSA-2408522 Selenoamino acid metabolism 4.137 × 10-3
2.2. MAT1A Expression Increases in Response to Chemotherapy in Bladder Cancer and Confers a
Survival Advantage
We identified MAT1A as one of the top significantly upregulated genes with a fold change value
of 6.66 and 3.40 in BL0293 and BL0440 relapsed tumors, respectively (Figure 2E). This finding was
validated through immunohistochemical analysis showing increased MAT1A protein abundance in
drug treated tumors (Figure 3B) compared to untreated controls (Figure 3A) and patient bladder tumor
tissue sections having received neoadjuvant chemotherapy (Figure 3D,E).
MAT1A is a low abundance transcript detected by RNA in a few human tissues (Figure S1A;
liver, ovary, pancreas, and testes) with evidence of high protein expression by immunohistochemistry
(IHC) in the human liver (Figure S1B) [10]. However, the human bladder has virtually undetectable
MAT1A RNA and protein levels, natively (Figure S1A,C) [10,11]. As such, MAT1A RNA expression is
not endogenous to any of the cells residing in the healthy urinary bladder, and MAT1A transcription
initiates in bladder cancer cells after the epithelia undergo oncogenic transformation [9]. To determine
whether MAT1A expression found in PDX models of bladder cancer relapse is also broadly observed in
tumors harvested from patients that received chemotherapy, we examined MAT1A protein expression
by IHC in bladder cancer biopsies from 55 patients (Table S2). The median age of these patients was 68
(36–85) and 81.8% were male, consistent with the reported higher incidence rates in men [12]. Eleven of
55 (20%) patients received chemotherapy, whereas 4/55 (7.27%) received Bacillus Calmette-Guerin
(BCG) as neoadjuvant therapy. We observed an increase in the nuclear, but not the cytoplasmic IHC
staining for MAT1A (Mean: 0.966 ± 0.42) compared to those whose prior treatment status was listed as
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“not reported” (Mean: 0.6468 ± 0.3568) or those previously treated with BCG (Mean: 0.6475 ± 0.454);
this difference was not quite significant (p = 0.0572), likely due to insufficient statistical power from a
limited sample size (Figure 3C). Figure 3D illustrates the typical IHC pattern observed for patients
sample with both cytoplasmic and nuclear staining, while Figure 3E illustrates human samples with
predominant cytoplasmic staining. However, our findings revealed that 100% of the patient samples
with reported neoadjuvant chemotherapy had some level of MAT1A protein expression, suggesting that
MAT1A protein expression correlates with chemotherapy treatment in human bladder tumors.
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Figure 2. RNA sequencing (RNA-seq) profiling identifies significant transcriptional changes in drug
treated bladder PDX tumors. (A) 351 and 402 genes were found significantly changed in BL0293 and
BL0440 drug-relapsed tumors; (B) 20 up-regulated and (D) 17 down-regulated genes where shared by
both drug-relapsed xenografts. (C) A heat map depicts variation of shared up- and down-regulated
genes among BL0293 and BL0440 biological replicates. M1 and M2 denote biological replicates. (E)
methionine adenosyltransferase 1a (MAT1A) gene expression values in sensitive (PBS) and drug treated
(Rx) tumors from RNA sequencing data, expressed in fold change (FC), for both BL0293 and BL0440.
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Figure 3. MAT1A protein levels increase in drug relapsed PDX and clinical patient tumors. MAT1A
protein expression was examined by immunohistochemical (IHC) analysis in (A) non-drug relapsed
and (B) drug relapsed BL0440 tumors. Images taken at 40×magnification, insets are enlargements of
image shown, white arrows highlighting regions of enhanced MAT1A abundance in chemotherapy
treated tumors. (C) MAT1A expression quantification across patient tissue microarrays (TMAs)
(n, nuclear; c, cytoplasmic). (D,E) Evaluation of TMA of bladder cancer samples obtained during
cystectomy. IHC analysis includes MAT1A protein stained with labeled streptavidin biotin (LSAB) and
counterstained with hematoxylin. (D) Sample showing nuclear and cytoplasmic localization of MAT1A
from male patient receiving six cycles of chemotherapy which included gemcitabine; (E) sample showing
only cytoplasmic MAT1A localization from male patient receiving Bacillus Calmette-Guerin (BCG).
MAT1A expression was next quantified in vitro, in 5637 human bladder cancer cells throughout a
48 h exposure to gemcitabine as well as during a 12 day post treatment recovery period (Figure 4A).
Baseline MAT1A transcription was low, but gradual increases in MAT1A mRNA levels were observed
starting at 24 h after the start f tre tment with an expression p ak two days following th removal of
gemcitabine, exclusively in the drug reated (5637Rx) samples. After day four, MAT1A tra scription
g adually decreased u til day 14, whe levels retu ned to approximate y the same baseline expression
levels measured prior to drug treatment (Figure 4B).
To further investigate the role of MAT1A in tumor relapse following gemcitabine treatment,
we overexpressed MAT1A in transient transfections of 5637 cells (5637MAT1A+) (Figure 4C) and
compared the gemcitabine IC50 profile of these cells to mock transfected controls. 5637MAT1A+ cells
had a significant two-fold higher level of MAT1A protein than 5637 control cells (Figure 4D,E) and
displayed ~100× increases in drug resistance, as evidenced by a change in IC50 concentration from
7.55×10−6 mM to 7.95×10−4 mM following exposure to a range of gemcitabine drug concentrations
(Figure 4F).
2.3. MAT1A Confers a Survival Advantage, Potentially Through Decreases in Active Transcription
and Proliferation
To obtain mechanistic insights into how MAT1A upregulation allows for such increases in drug
tolerability as evidenced by dose response analysis (Figure 4F), we conducted RNA-seq on 5637MAT1A+
cells and compared their transcript levels to those from empty vector transfected 5637 control cells
(5637) (Figure S2. An ontology analysis was conducted and revealed downregulation in many
senescence related pathways (Table S3). Upregulated genes did not show enrichment for any relevant
ontology categories.
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Figure 4. MAT1A is upregulated in cells that survive 48 h drug treatment and overexpression alters cell
response to gemcitabine. (A) 5637 cells were dosed at ~80% IC50 gemcitabine concentration (0.3 µM)
for 48 h in vitro. RNA was collected from remaining gemcitabine treated (5637Rx, n = 3) and untreated
cells (5637, n = 3) before (day zero), during (day one, two) and after (day three, four, six, nine, and 12)
drug treatment. (B) MAT1A expression was quantified via qPCR at each timepoint and expressed
in FC. Statistical analysis was conducted using Student’s t-test, p < 0.0005 (#). (C) Quantitative PCR
showing relative MAT1A gene expression in MAT1A plasmid transfected 5637 bladder cancer cells
(5637MAT1A+) expressed as FC, (n = 3 biological replicates), p < 0.0005 (#) compared to expression at day
four in post drug treated 5637 cells (5637Rx) (NS, non-significant). (D) Representative gel of MAT1A
protein expression relative to control b-tubulin analyzed via Western blotting using the Jess system
(ProteinSimple). (E) Normalized MAT1A/b-tubulin protein expression calculated using Jess system
densitometry expressed as percent of wildt pe MAT1A expression in 5637 control cells (n = 6 biological
replicates), p < 0.005 (**). (F) IC50 gemcit bine drug toxicity curve between empty vector transfected
and MAT1A transfected cells (n = 5 biological replicate per conditio per dose).
Gemcitabine is a chemotherapeutic which relies on the highly proliferative nature of cancer cells
to exert an anti-cancer effect, thus, we hypothesized that MAT1A overexpression could influence
proliferative ability. Proliferative indices were calculated via flow cytometric analysis and computational
models utilizing FlowJo software. Over four days in culture, MAT1A overexpressing cells had a lower
proliferation index (PI: 3.84) compared to control (PI: 3.99), (Figure 5A). Percentages of total live cells in
each generation of a total cell population were also calculated. In generations two and three, there was
a statistically significantly greater percentage of MAT1A overexpressing cells compared to control.
Additionally, 86% of 5637MAT1A+ cells were found in generation four compared to 91% of control cells
(Figure 5B). Further, 70 of 221 (31%) of downregulated genes were transcription factor encoding genes
and belonged to protein families associated with a transcriptionally active cell state: Zinc finger motifs,
histones, and additional transcription factors (Figure 5C–E).
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Figure 5. MAT1A overexpression decreases cell proliferation and transcriptional activity. (A)
Proliferation indices over 72 h (* p < 0.05) in 5637 and 5637MAT1A+ cells and (B) percentage of 5637 versus
5637MAT1A+ cells in various generations following initial cell seeding at generation zero (* p < 0.05).
Cells were stained with carboxyfluorescein diacetate succinimidyl ester (CFSE) and analyzed using
flow cytometry to evaluate changes in proliferation. Data was analyzed and proliferation was modeled
in FlowJo®. RNA-seq analysis identified whole genome transcriptomic alterations in 5637MAT1A+ and
5637 cells. Heat maps representing differentially expressed genes (n = 3 biological replicates) reveal
downregulation in three gene groups: (C) zinc finger, (D) histone, and (E) transcription factors.
3. Discussion
The cancer field is rapidly moving towards developing new strategies for more effectively
prolonging life for those afflicted by highly aggressive cancer types. These include changing the
formulation of chemotherapy by prescribing multi-drug regimens instead of one chemotherapeutic at
a time. Gemcitabine has been the backbone of neoadjuvant chemotherapy for many cancer subtypes,
and it has been undoubtedly an effective strategy for shrinking tumors prior to surgery, contributing to
a prolonged life span [13]. However, in a recent clinical trial, patients diagnosed with early stage
pancreatic ductal carcinoma treated with FOLFIRINOX, a mixture of four chemotherapy drugs
(fluorouracil [5-FU], leucovorin, irinotecan, and oxaliplatin) had a substantially increased survival [14],
emphasizing the need to continue to develop multi-drug formulations. Despite these improvements
most of these patients continue to succumb to drug relapse [15]. Therefore, understanding the
underlying molecular mechanisms of relapse following drug treatment in cancer model systems
will provide valuable information to expand the treatment options for patients with re-emerging
tumors [16].
Several studies have provided supporting evidence that genes involved in methionine metabolic
pathways tend to be altered in a variety of cancer types, hinting that this pathway may be involved in
various aspects of tumorigenesis [12–14]. Our work strengthens this observation and provides new
mechanistic evidence that alterations of this pathway directly affect drug tolerance to gemcitabine
and contributes to the emergence of drug relapse in bladder cancer patient derived xenograft models.
Here we show that elevated levels of MAT1A significantly alter chemosensitivity over a wide range of
gemcitabine doses, and that this phenotype was directly mediated by MAT1A (Figure 4). Therefore,
we may speculate that inhibiting MAT1A function in cancer cells might be beneficial in enhancing drug
responsiveness. However, future studies will need to address whether attempting to repress MAT1A
in vivo can improve cancer outcomes [17].
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MAT1A belongs to a family of methyltransferases that contribute to methylation of a variety of
molecules including DNA and histones, via synthesis of SAM [18]. In cancer research, MAT1A has
been mostly described in the context of hepatocellular carcinoma (HCC), where it was previously
shown that a switch in gene expression from MAT1A to MAT2A (M1-M2 switch) promoted cancer
invasion and metastasis. One study showed that enhancing the M1-M2 switch promoted the ability
of these cancer cells to metastasize, and this phenomenon was correlated with human data where a
balance in favor of M2 (M1 < M2) correlated with increased metastasis and high rate of recurrence
in HCC patients. Mechanistically this work highlighted that MAT1A was essential for methylating
the promoters of certain genes such as osteopontin (OPN), and by repressing MAT1A expression
such genes were freed from methylation-dependent repression and corroborated with other MAT1A
activated genes to promote metastasis-driving pathways such as extracellular-signal-regulated kinase
(ERK) signaling [19]. Our study however, finds the expression to be tipped in favor of M1 in the
bladder, and the downstream outcomes of M1 overexpression may have broader implications including
increased survivability in the presence of chemotherapy. Our findings provide novel mechanistic
insights into the emergence of drug resistance in bladder cancer. Natively, MAT1A has a tissue specific
expression pattern with robust expression in liver, pancreas, skin, ovaries, and testis tissues and has
been previously characterized in the context of hepatocellular carcinoma [20]. Our findings further
highlight that expression of MAT1A in extrahepatic tissue associates with poor prognosis. Interestingly,
MAT1A is not expressed in the urinary bladder under normal conditions, further suggesting the
importance of this work as a novel biomarker for bladder cancer (Figure S1). Further research will be
needed to evaluate utility of MAT1A as a biomarker across other cancer types in tissues where MAT1A
is not natively expressed, as an indicator of aggressiveness and/or relapse post treatment.
Since MAT1A has been previously shown to repress gene expression via DNA methylation of gene
promoters, it is possible that the down-regulation of histone genes observed in cells overexpressing
MAT1A may be caused by direct methylation of these promoters. Alternatively, MAT1A may methylate
histones and contribute to a regulatory feedback. Since the discovery of RNA methyltransferases a few
years ago, this area is now receiving increased attention as a new regulatory mechanism of controlling
gene expression [21]. This new layer of regulation is termed “epitranscriptomics.” Similar to MAT1A,
RNA methyltransferases, demethylases, and m6A-binding proteins are frequently upregulated in
human cancer tissues from a variety of organ origins. While their expression levels have not yet
been examined in the context of drug resistance, elevated levels of these genes are correlated with
cancer progression and metastasis. While the biochemistry of MAT1A has been mostly examined in
the context of DNA methylation, addition work is required to determine whether this enzyme also
contributes to other types of methylation, including RNA and histone protein methylation. Additionally,
ultrasensitive quantification of SAM-derived methyl groups will further elucidate differences in DNA,
RNA, and histone protein methylation to provide insight into whether SAM-mediated epigenetic
modifications through MAT1A provide cancer cells with a drug resistant phenotype. DNA methylation,
histone modifications, and the chromatin structure are profoundly altered in human cancers and
future studies will further determine how MAT1A is involved in some of these processes to contribute
to drug resistance, in bladder, and possible other types of cancer. The work presented here has
clinical relevance as well as applications in basic research. Evidence of MAT1A in bladder tumors may
prove as a powerful prognostic tool to evaluate surgical margins and indicate likelihood of relapse in
histopathology samples. Lastly, association of MAT1A with drug resistant cell populations may also
lead to new small molecule inhibitors capable of eliminating drug resistant cells that ultimately allow
tumor relapse.
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4. Materials and Methods
4.1. Bladder Cancer Patient Derived Xenografts
Bladder cancer xenografts (BL0293 and BL0440) were previously described with corresponding
drug sensitivity data [9]. Frozen samples from Passage 4 were propagated in NSG (NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ) immunodeficient mice (The Jackson Laboratory, Bar Harbor, ME, USA) by injecting
single cell suspensions (3 × 106 tumor cells administered in 100 µL volume of cell suspension in 1:1
Matrigel (Corning)) subcutaneously (SQ) into the right flank. Tumor burden was assessed by measuring
tumor length and width using digital calipers twice per week for up to 10 weeks. Tumor volume was
estimated using the formula (length*width2)/2. Tumors were excised when they reached an estimated
volume of 1 cm3 or when other IACUC criteria were met. All animal experiments were approved
by the Lawrence Livermore National Laboratory Institutional Animal Care and Use Committee and
conform to the Guide for the care and use of laboratory animals. Protocol 168 was approved October
14, 2015 by LLNL IACUC to conduct this work.
4.2. Generation of Drug Relapsed PDX Tumors
Gemcitabine hydrochloride (BioVision, Inc, Milpitas, CA, USA) was dissolved in PBS at a final
concentration of 25 mg/mL and administered intraperitoneally (IP) once per week for four consecutive
weeks at 150 mg/kg. Concurrently, cisplatin (Spectrum Chemical Mfg Corp, New Brunswick, NJ,
USA) was resuspended in PBS at 1 mg/mL and delivered intravenously (IV) at 2 mg/kg per animal.
Cisplatin dosing occurred on days one, two, and three and days 15, 16, and 17 of drug treatment.
Control animals (n = 3) were treated with an equivalent amount of PBS at the same time as chemotherapy
treatment. Tumors were grown in vivo for up to 65 days (n = 5).
4.3. RNA Sequencing
Harvested tumors were minced and manually dissociated using a 40 µm cell strainer. Tumor cells
were flash frozen in liquid nitrogen and stored at −80 ◦C until processed. RNA was isolated from 6
x 106 homogenized cells by using QIAshredder and RNeasy® Mini Qiagen kits (Hilden, Germany).
RNA concentrations were quantified using a Qubit® RNA HS Assay Kit (ThermoFisher Scientific,
Waltham, MA, USA). Quality was assessed before sequencing using an RNA 6000 Nano kit run on
an Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA, USA). cDNA libraries were
prepared from 100 ng of total isolated RNA per manufacturer specification from BL0293/BL0440 in vivo
tumors or in vitro 5637 bladder cancer cells for RNA sequencing using Illumina TruSeq RNA Library
Preparation kit version 2.0 (Illumina Inc., San Diego, CA, USA) and run on an Illumina Nextseq 500
using the High Output 75 cycles kit (Illumina Inc., San Diego, CA, USA).
4.4. RNA Sequencing Data Analysis
Read quality from RNA-seq raw data was first assessed using FastQC [22]. Sequence data was
aligned to the human genome (hg19) using TopHat2 and STAR [23]. Subsequently, gene-wise read
counts were calculated using ‘featureCounts’ from Rsubread package. Then, the count data was
normalized using TMM normalization method, and differentially expressed genes were identified
using ‘limma’ [24] and ‘voom’ [25]. Genes that were >1.5 fold up- or down-regulated with an FDR
corrected p-value <0.05 were considered significantly differentially expressed. Pathway ontology
analysis was conducted using ToppGene tool using p-value < 0.05 to denote process significance [26].
4.5. Plasmid Transfection Generating 5637MAT1A+ Cells
5637 bladder cancer cell line was obtained from ATCC. MAT1A plasmid (Origene; NM_000429
Human Untagged Clone, Product #SC119881) was isolated and purified using MidiPrep™ kit
(Qiagen Inc., Hilden, Germany). Subconfluent 5637 cells were transfected with MAT1A plasmid DNA
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(2 µg/µL) using a Lipofectamine 3000 kit following manufacturer guidelines (ThermoFisher Scientific,
Waltham, MA, USA). Briefly, liposomes containing plasmid DNA were constructed in low serum media
and added to cells of interest. Transfection occurred over 48 h, followed by downstream experimental
procedure. Control experiments were carried out with an empty expression vector.
4.6. Immunohistochemical Analysis
PDX tumors were prepared for IHC analysis by fixation in 10% neutral buffered formalin for
three to four days. Tumors were stored in 70% isopropanol until ready for embedding in Type IV
paraffin. Tumors were sectioned using a Leica Biosystem RM2125 microtome to collect 0.2 µm tissue
sections. Sections were counterstained with hematoxylin and protein of interest was probed using
MAT1A primary antibody (ab174687) and labeled streptavidin biotin (LSAB) secondary antibody.
4.7. Human Patient Tissue Microarray Analysis (TMA)
Human bladder cancer tissue microarray (TMA) sections were obtained from the Biorepository at
UC Davis Comprehensive Cancer Center. Patient characteristics are described in Table S3. TMAs were
stained for MAT1A expression using previously described methods in ‘Immunohistochemical Analysis’
section. Each patient tissue was used in triplicate in the TMA, and were scored individually in the
nucleus and the cytoplasm, as 0, 0.25, 0.5, 0.75, 1.0, or 1.5, representing increasing fraction of cells
staining for MAT1A.
4.8. The Human Protein Atlas: MAT1A
MAT1A expression in normal human liver and bladder tissues was used for comparison to
expression in bladder tumors, shown in this study (Figure S1). MAT1A expression in bladder and liver
tissue made available through v19.proteinatlas.org, available from http://www.proteinatlas.org [11].
Figure S1B available through https://www.proteinatlas.org/ENSG00000151224-MAT1A/tissue/liver#img.
Figure S1C available through: https://www.proteinatlas.org/ENSG00000151224-MAT1A/tissue/urinary+
bladder#img.
4.9. Western Blotting and Protein Analysis
Proteins were isolated from flash frozen tumor cells or 5637 cells in RIPA lysis buffer (Sigma Aldrich
Corporation, St. Louis, MO, USA) followed by centrifugation at 14,000 rcf for 5 min. The supernatants
were collected and analyzed using the Jess automated Western blotting system (ProteinSimple, San Jose,
CA, USA). Jess reagents (biotinylated molecular weight marker, streptavidin-HRP fluorescent standards,
sample buffer, DTT, stacking matrix, separation matrix, running buffer, wash buffer, matrix removal
buffer, fluorescent labeled secondary antibodies, antibody diluent, and capillaries) were used according
to the manufacturer’s standard protocol. Antibodies were diluted with ProteinSimple antibody diluent
as follows: MAT1A primary antibody (undiluted, Abcam, Cambridge, United Kingdom, ab174687),
beta-Tubulin (1:100, LI-COR Biosciences, Lincoln, ME, Catalog no. 926-42211). Protein concentration
was quantified using Compass for SW 4.0 software. Target protein abundance is normalized to the
expression of beta-tubulin.
4.10. In Vitro Toxicity
5637MAT1A+ and 5637 cells were dosed with a range of gemcitabine concentrations from
0 mM to 30 mM for 48 h post plasmid transfection. Cell viability was assessed at 48 h
post drug treatment using an ATP-based cell viability assay following manufacturer guidelines
(CellTiterGlo 2.0, Promega Corporation, Madison, WI, USA). IC50 values were calculated using Prism
8 (GraphPad Software Inc., La Jolla, CA, USA).
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4.11. Quantitative PCR (qPCR)
Total RNA was isolated using a commercially available RNeasy Mini Kit (Qiagen, Hilden,
Germany). RNA was reverse transcribed to generate cDNA using a SuperScript IV First Strand
Synthesis Kit (ThermoFisher Scientific). Cycling was performed using a Fast Real-Time System
on an Applied Biosystems 7900HT instrument. Cycling conditions using SYBR as a DNA dye
are as follows: 50 ◦C for 2 min, 95 ◦C for 2 min followed by 40 cycles of 95 ◦C for 3 s then
60 ◦C for 40 s. Data was normalized to Ct values of GAPDH (control gene) and reported as
fold change, calculated using the standard ddCt method. GAPDH primer sequences: Forward,
GTCTCCTCTGACTTCAACAGCG; reverse, ACCACCCTGTTGCTGTAGCCAA. MAT1A primer
sequences: Forward, TCATGTTCACATCGGAGTCTGT; reverse, CATGCCGGTCTTGCACACT.
4.12. Cell Proliferation
5637 cells transfected with MAT1A plasmid or a control empty vector were seeded at 20% confluency
(n = 6) and dyed using the CellTrace™ CFSE Cell Proliferation Kit, to quantify cell proliferation.
All cells were collected three days post-transfection and immediately analyzed for fluorescence using a
FACSMelody™ flow cytometer (Becton, Dickinson & Co, Franklin Lakes, NJ). Expansion indices as
well as proliferation/division indices were determined using cell proliferation modeling generated by
FlowJo flow cytometry software (FlowJo, LLC, Ashland, OR, USA). Statistics were performed using a
Student’s t-test including n = 6 biological replicates from each 5637 and 5637MAT1A+ cells.
4.13. Statistical Analysis
In vitro analysis: Data is presented as averages +/− standard deviation. Student’s t-test was used
to calculate statistical significance in Microsoft Excel. TMA analysis of human tissues: Median of three
values from each patient were first calculated and then mean and standard deviation derived in each
group. MAT1A expression was compared between patients with and without prior treatment or statin
or between those with chemotherapy or BCG using Mann-Whitney non-parametric tests. Analyses were
conducted using GraphPad Prism 8.2. p values of less than 0.05 were deemed statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/20/
4983/s1.
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Abbreviations
MAT1A Methionine adenosyltransferase 1a
PDX Patient-derived xenograft
SAM S-adenosylmethionine
CIS cisplatin
GEM gemcitabine
NSG NOD scid gamma
Rx drug treated
PBS phosphate buffered saline
FC fold change
ATP adenosine triphosphate
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PCR polymerase chain reaction
CFSE carboxyfluorescein diacetate succinimidyl ester
HCC Hepatocellular carcinoma
OPN osteopontin
SQ subcutaneous
IHC immunohistochemical
TMA tissue microarrays
FOLFIRINOX Leucovorin, fluorouracil, irinotecan, oxaliplatin
BCG Bacillus Calmette-Guerin therapy
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